S
Shanghai Zeideman Pharmaceutical Technology
Innovative small molecule drugs for immune-mediated diseases, addressing major clinical needs in CNS, respiratory, and skin conditions
About Shanghai Zeideman Pharmaceutical Technology
Thederma focuses on the research and development of innovative drugs targeting immune-mediated diseases, particularly in the fields of central nervous system (CNS), facial features, respiratory, and skin diseases. The company operates in the biopharmaceutical market, serving clinicians and patients with unmet clinical needs. Thederma's business model revolves around the discovery and development of small molecule drugs, leveraging a unique and highly differentiated product portfolio. The company generates revenue through the commercialization of these innovative drugs, aiming to provide better treatment options for clinicians and improve patient outcomes. The management team boasts extensive experience in drug R&D, technology, capital, and industry, ensuring efficient and rapid medical transformation and marketing of their products.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 20.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Oct 2024 | $14M | $55M | Hankang Capital · Qingdao Guoxin Group | ↗ |
| SERIES A✓Equity / VC | Mar 2023 | $14M | $55M | Hankang Capital · Bainuo Capital · Betta Fund | ↗ |
Growth signals
Latest recorded traffic for Shanghai Zeideman Pharmaceutical Technology is 470 monthly website visits, up 62.1% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shanghai Zeideman Pharmaceutical Technology in its local ecosystem
The Shanghai Zeideman Pharmaceutical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- BCBainuo Capital
Hankang Capital- BFBetta Fund
Qingdao Guoxin Group
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai Zeideman Pharmaceutical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Zeideman Pharmaceutical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









